Tandem Diabetes Care (TNDM) Gross Margin (2013 - 2026)
Tandem Diabetes Care (TNDM) posted Gross Margin of 55.33% for Q1 2026, down 4.05% on a QoQ basis from 57.67% in Q4 2025, and up 482.0% year-over-year from 9.51% in Q1 2025.
Tandem Diabetes Care (TNDM) Gross Margin (2013 - 2026) Analysis & Trends
Tandem Diabetes Care's Gross Margin history runs 14 years deep, the most recent figure standing at 55.33% for Q1 2026.
- Quarterly Gross Margin rose 482.0% year-over-year to 55.33% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 54.93% (up 271.0% YoY) and the FY2025 annual result came in at 53.81%, up 174.0% from the prior year.
- Gross Margin was 55.33% for Q1 2026 at Tandem Diabetes Care, down from 57.67% in the prior quarter.
- Across five years, Gross Margin topped out at 57.67% in Q4 2025 and bottomed at 47.41% in Q4 2023.
- A 5-year average of 51.73% and a median of 51.09% in 2024 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2023 — Gross Margin slumped 498 bps — and 2024, when it surged 830 bps.
- Tandem Diabetes Care's Gross Margin stood at 52.39% in 2022, then declined by 10 bps to 47.41% in 2023, then advanced by 18 bps to 55.71% in 2024, then climbed by 4 bps to 57.67% in 2025, then slipped by 4 bps to 55.33% in 2026.
- Business Quant data shows TNDM's Gross Margin at 55.33% in Q1 2026, 57.67% in Q4 2025, and 53.88% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 56.20% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 63.29% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 65.35% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 69.46% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 78.01% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 62.95% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 45.22% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 38.53% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Tandem Diabetes Care | 1.16 Bn | 587.46 Mn | 136.79 Mn | 55.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 55.33% |
| Dec 31, 2025 | 57.67% |
| Sep 30, 2025 | 53.88% |
| Jun 30, 2025 | 52.29% |
| Mar 31, 2025 | 50.51% |
| Dec 31, 2024 | 55.71% |
| Sep 30, 2024 | 51.09% |
| Jun 30, 2024 | 50.83% |
| Mar 31, 2024 | 49.39% |
| Dec 31, 2023 | 47.41% |
| Sep 30, 2023 | 48.35% |
| Jun 30, 2023 | 51.93% |
| Mar 31, 2023 | 48.95% |
| Dec 31, 2022 | 52.39% |
| Sep 30, 2022 | 51.05% |
| Jun 30, 2022 | 50.91% |
| Mar 31, 2022 | 51.78% |
| Dec 31, 2021 | 54.16% |
| Sep 30, 2021 | 53.86% |
| Jun 30, 2021 | 53.71% |